The Patent Finder

RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality

Phio Pharmaceuticals Corp.

A patent family: one line of work, grouped by real continuity rather than by a technology label inferred from titles. 3 of these applications claim priority to application PCT/US2010/000348, filed Feb 4, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
PatentTitleHolderStatusExpiresTime remainingConfidence
US 9,745,574RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
In force
 · High confidence
Phio Pharmaceuticals Corp.In force
High confidence
US 10,479,992RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
In force
 · Medium confidence
Phio Pharmaceuticals Corp.In force
Medium confidence
US 11,667,915RNA Duplexes with Single Stranded Phosphorothioate Nucleotide Regions for Additional Functionality
In force
 · Medium confidence
Phio Pharmaceuticals Corp.In force
Medium confidence
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited